Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 12:21:169-176.
doi: 10.1016/j.jare.2019.10.005. eCollection 2020 Jan.

Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

Yanguang Cong  1 , Sijin Yang  2 , Xiancai Rao  3
Affiliations
Review

Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features

Yanguang Cong et al. J Adv Res. .

Abstract

The infection caused by methicillin-resistant Staphylococcus aureus (MRSA) is a global threat to public health. Vancomycin remains one of the first-line drugs for the treatment of MRSA infections. However, S. aureus isolates with complete resistance to vancomycin have emerged in recent years. Vancomycin-resistant S. aureus (VRSA) is mediated by a vanA gene cluster, which is transferred from vancomycin-resistant enterococcus. Since the first VRSA isolate was recovered from Michigan, USA in 2002, 52 VRSA strains have been isolated worldwide. In this paper, we review the latest progresses in VRSA, highlighting its resistance mechanism, characteristics of VRSA infections, as well as clinical treatments.

Keywords: Treatment; Vancomycin; Vancomycin-resistant Staphylococcus aureus; vanA cluster.

PubMed Disclaimer

Conflict of interest statement

The authors have declared no conflict of interest

Figures

None
Graphical abstract
Fig. 1
Fig. 1
Resistant mechanism of vancomycin-resistant Staphylococcus aureus. (a) Schematic diagram of normal peptidoglycan synthesis. (b) Schematic diagram of vancomycin action. (c) Organization of the vanA cluster. (d) Resistant mechanism of vancomycin-resistant S. aureus. D-Ala: D-Alanine; D-lac: D-lactate; L-Lys: L-Lysine; D-Glu: D-glutamate; Gly5: Pentaglycine; NAM: N-acetylmuramic acid; NAG: N-acetylglucosamine.
Supplementary Fig. 1
Supplementary Fig. 1
See this image and copyright information in PMC

References

    1. Rasigade J.P., Vandenesch F. Staphylococcus aureus: a pathogen with still unresolved issues. Infect Genet Evol. 2014;21:510–514. - PubMed
    1. Chambers H.F., Deleo F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol. 2009;7(9):629–641. - PMC - PubMed
    1. Taylor TA, Unakal CG. Staphylococcus aureus, in StatPearls. Treasure Island; FL: 2019.
    1. Kim C., Milheirico C., Gardete S., Holmes M.A., Holden M.T., de Lencastre H. Properties of a novel PBP2A protein homolog from Staphylococcus aureus strain LGA251 and its contribution to the beta-lactam-resistant phenotype. J Biol Chem. 2012;287(44):36854–36863. - PMC - PubMed
    1. Hartman B.J., Tomasz A. Low-affinity penicillin-binding protein associated with beta-lactam resistance in Staphylococcus aureus. J Bacteriol. 1984;158(2):513–516. - PMC - PubMed

LinkOut - more resources